Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

BACKGROUND: Isocitrate dehydrogenase 1 (IDH1) mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma, a relatively uncommon cancer with a poor clinical outcome. The aim of this international phase 3 study was to assess the efficacy and safety of ivosidenib (AG-120)—a s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Oncol
Autors principals: Abou-Alfa, Ghassan K, Macarulla, Teresa, Javle, Milind M, Kelley, Robin K, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V, Borad, Mitesh J, Bridgewater, John, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Fan, Bin, Wu, Bin, Chamberlain, Christina X, Jiang, Liewen, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Zhu, Andrew X
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523268/
https://ncbi.nlm.nih.gov/pubmed/32416072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30157-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars